Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer

Gastric Cancer

Volumn 6, Issue 3, 2003, Pages 153-158

  Yoshioka, Takashi ^a   Sakata, Yuh ^b   Terashima, Masanori ^c   Sekikawa, Kouji ^d   Gamoh, Makio ^e   Mitachi, Yasushi ^f   Saitoh, Soh ^g   Kanamaru, Ryunosuke ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b Misawa City Hospital   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^e OGAKI MUNICIPAL HOSPITAL   (Japan)

^f SENDAI KOUSEI HOSPITAL   (Japan)

^g AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Chemotherapy; Docetaxel (TXT); Gastric cancer; Irinotecan (CPT 11)

Indexed keywords

DOCETAXEL; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FEMALE; HUMAN; INOPERABLE CANCER; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT CANCER; SENSORY NEUROPATHY; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS; TAXOIDS;

EID: 0141996272     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-003-0244-5     Document Type: Article

References (22)

1. Cancer Statistics in Japan 2001. http://www.ncc.go.jp/en/statistics/2001/index.html
2. Wils J. The treatment of advanced gastric cancer. Semin Oncol 1996;23:397-406.
3. Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer; a phase II trial. Ann Oncol 1991;2:751-4.
4. Klein HO, Wickramanayake PD, Dieterle F, Mohr R, Oerkermann H, Gross R. High-dose MTX / 5-FU and adriamycin for gastric cancer. Semin Oncol 1983;10:29-31.
5. Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990;17:61-70.
6. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, et al. A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5:609-16.
7. Wils J, Klein HO, Wagener DJT, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 1991;9:827-31.
8. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
9. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Custem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57.
10. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
11. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. Late phase II clinical study of RP56976 (Docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (Group A). Jpn J Cancer Chemother 1998;25:1915-24.
12. Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. A late phase II clinical study of RP56976 (Docetaxel) in patients with advanced or recurrent gastric cancer: a Japanese Cooperative Study Group trial (Group B). Jpn J Cancer Chemother 1999;26:1487-96.
13. Hyodo I, Ohtsu A, Shirao K, Miyata Y, Saito H, Taguchi T. Late phase II study of paclitaxel (BMS-181339) in patients with advanced/recurrent gastric cancer; a Japanese Cooperative Study Group trial (group A). The 38th Annual meeting of Japan Society for Cancer Therapy 2002;35:443.
14. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 1994;21:1033-8.
15. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur - 0.4 M gimestat - 1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
16. Ringel I, Horwitz SB. Studies with RP56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991;83:288-91.
17. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49: 5077-82.
18. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
20. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. First English Ed. Tokyo: Kanehara; 1995.
21. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
22. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-9.